Granted Patent B2

US 9,931,415 · App. 14/434,823 · Granted Apr 3, 2018

Abstract

Claims (21)

1. A conjugate of formula ConjA:

where Ab is an antibody which is an antibody that binds to CD25, the antibody comprising:

a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ ID NO. 3, a VH CDR2 with the amino acid sequence of SEQ ID NO. 4, and a VH CDR3 with the amino acid sequence of SEQ ID NO. 5; and

wherein the drug loading is from 1 to about 8.

2. The conjugate according to claim 1 wherein the antibody comprises a VH domain having the sequence according to SEQ ID NO. 1.

3. The conjugate according to claim 1 wherein the antibody comprises:

a VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO. 6, a VL CDR2 with the amino acid sequence of SEQ ID NO. 7, and a VL CDR3 with the amino acid sequence of SEQ ID NO. 8.

4. The conjugate according to claim 1 wherein the antibody comprises a VL domain having the sequence according to SEQ ID NO. 2.

5. The conjugate according to claim 1 wherein the antibody is an intact antibody.

6. The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced.

7. The conjugate according to claim 1 wherein the antibody is a fully human monoclonal IgG1 antibody.

8. The conjugate according to claim 1 , wherein the drug loading is 1, 2, 3, or 4.

9. A mixture of the conjugates according to claim 1 wherein the average value of the drug loading is about 2 to about 5.

10. The conjugate according to claim 1 , wherein said conjugate comprises one of more conjugates selected from the group consisting of ConjA, ConjD and ConjE for use in treating a CD25 overexpressing cancer.

11. The conjugate according to claim 1 , wherein the conjugate is ConjE.

12. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.

13. The pharmaceutical composition of claim 12 further comprising a therapeutically effective amount of a chemotherapeutic agent.

14. A method of treating a CD25 overexpressing cancer comprising administering to a patient the pharmaceutical composition of claim 12 wherein said conjugate comprises one of more conjugates selected from the group consisting of ConjA, ConjD and ConjE.

15. The method of claim 14 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

16. The method of claim 14 wherein said conjugate is ConjE.

17. The conjugate according to claim 7 wherein the antibody is IgG1,κ.

Assignments (9)